Muriel Siebert, founder of Siebert Financial Corp. (NASDAQ: SIEB), passed away over the weekend. Many new investors may not know her nor may they know just how important and influential she was on Wall Street and in the financial services industries. Ms. Siebert died at the age of 80 years old, and we wanted to list some of her accomplishments that have led to at least more equality among women in what had been a men-only club before she came on the stage.
First and foremost, “Mickie” became the first woman to own a seat on the New York Stock Exchange by purchasing a seat back in 1967. She was also the first woman to head up an NYSE member firm. Most investors will think of Schwab as the first or most well known of the large discount brokerage firms, but Siebert made the move to a discount broker in the mid-1970s after NYSE members finally were�allowed to start negotiating their commission rates.
Siebert was one of the loudest voices when it came to equality for women on Wall Street and in other fields. Siebert may not have grown into the beasts that other online and discount brokerage firms grew into, but sometimes a founder and leader is happy enough with what they have. Her firm’s shares rose with the rise of the discount brokerage firms and the tech bubble in the late 1990s, but that wave came and went and Siebert’s firm had not been discussed much since.
5 Best Income Stocks To Buy Right Now: Schawk Inc.(SGK)
Schawk, Inc., together with its subsidiaries, provides graphic services and solutions in the Americas, Europe, and the Asia Pacific. The company?s graphic services encompasses a range of creative and executional service offerings, including traditional premedia business services, as well as digital photography, color retouching, large format digital printing, and sales and promotional samples under the Schawk brand name; and digital three-dimensional modeling of prototypes or existing packages for its consumer products clients. Its brand and package strategy and design services include brand consulting and creative design for packaging applications to consumer products companies, food and beverage retailers, and mass merchandisers under the Brandimage and Anthem brands. The company also offers digital promotion and advertising services to the digital communications markets under the Untitled and Real Branding brand names. In addition, it provides software products, such a s graphic lifecycle content management systems comprising digital asset management, workflow management, online proofing, and intelligence performance management modules; and support services, which include implementation, on-site management, validation for regulated environments, and support and training for the marketing services departments of consumer products, pharmaceutical/life sciences, and retail companies. The company serves direct purchasers of graphic services, including end-use consumer product manufacturers of food, beverage, non-food and beverage, and pharmaceutical products; groceries, pharmacies, department, and mass merchant retailers; converters; and advertising agencies. Schawk, Inc. was founded in 1953 and is headquartered in Des Plaines, Illinois.
Advisors' Opinion:- [By Seth Jayson]
There's no foolproof way to know the future for Schawk (NYSE: SGK ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.
Top Tech Stocks To Buy For 2014: Teradata Corporation(TDC)
Teradata Corporation provides analytic data solutions worldwide. The company offers various data warehousing solutions that comprise software, hardware, and related business consulting and support services. Its solutions integrate an organization?s departmental and enterprise-wide data about customers, financials, operations, and others into a single enterprise-wide data warehouse. The company also provides various software and hardware products, including Teradata Analytic Database Software, which delivers near real-time intelligence; Teradata Platform Family for the hardware component; Teradata Logical Data Models that are blueprints for designing an integrated data warehouse; Teradata Aster MapReduce Platform, a platform for analyzing new multi-structured data sources and data types; and Teradata Integrated Analytics to convert traditional data warehouse into an analytic services environment. In addition, it offers Teradata Analytic Applications and Tools comprising da ta mining, master data management, integrated marketing management, enterprise risk management, finance and performance management, demand and supply chain management, and profitability analytics to solve business problems. Further, the company provides consulting services, such as data warehousing business impact modeling, design, architecture, installation, implementation, and optimization consulting services, as well as enterprise analytics consulting, data management, and managed services; customer support services; and training services. It serves various companies in banking/financial services, media and entertainment, government, insurance and healthcare, manufacturing, retail, telecommunications, transportation, and travel industries. The company has strategic partnerships with Accenture, Capgemini, Cognizant, Computer Sciences Corporation, Deloitte, IBM Global Business Services, and Wipro Limited. Teradata Corporation was founded in 1979 and is headquartered in Dayt on, Ohio.
Advisors' Opinion:- [By Paul Ausick]
Stocks on the Move: J.C. Penney Co. Inc. (NYSE: JCP) is down 9% at $7.16 after posting a new 30-year low today. Molycorp Inc. (NYSE: MCP) is down 21.5% at $5.58 after announcing a secondary stock offering. Teradata Corp. (NYSE: TDC) is down 18.4% at $42.92 on disappointing guidance.
- [By Luke Jacobi]
Teradata (NYSE: TDC) shares tumbled 18.39 percent to $42.91 after the company issued downbeat earnings forecast for the full year.
FLIR Systems (NASDAQ: FLIR) sold off 13.81 percent to $28.59 after the company released some poor guidance.
- [By Wallace Witkowski]
Shares of Teradata (TDC) �fell 11% to $46.65 on heavy volume after the company said it now expects adjusted full-year earnings of $2.70 to $2.80 a share. Analysts surveyed by FactSet expect earnings of $2.85 a share.
Top Tech Stocks To Buy For 2014: Actelion Ltd (ATLN.VX)
Actelion Ltd is a Swiss biopharmaceutical holding company that focuses on the discovery, development and commercialization of small molecule drugs. The Company has four approved drugs on the market: Tracleer, an oral dual endothelin receptor antagonist; Veletri, a prostanoid vasodilator; Ventavis, an inhaled formulation of iloprost, and Zavesca, an oral treatment for type 1 Gaucher disease. Furthermore, the Company has a number of compounds various stages of development. The Company operates through a number of worldwide subsidiaries, including Actelion Registration Ltd, which holds marketing authorizations for products marketed in the European Union; Actelion Clinical Research, Inc, engaged in clinical development on behalf of the Company's group; Actelion Re SA, providing insurance solutions for the Company's group and Actelion US Holding Company, engaged in the holding activities of the Company's United States-based units. In September 2013, it acquired Ceptaris Therapeutics, Inc. Advisors' Opinion:- [By Victor Selva]
Forest Laboratories has a current ratio of 2.69% which is higher than the ones registered by Endo International Plc (ENDP), Valeant Pharmaceuticals International (VRX) and Cubist Pharmaceuticals Inc. (CBST). For investors looking for a higher ROE, Allergan Inc. (AGN) and Actelion Ltd. (ATLN.VX) are good options.
Top Tech Stocks To Buy For 2014: KYTHERA Biopharmaceuticals Inc (KYTH)
KYTHERA Biopharmaceuticals, Inc., incorporated in June 2004, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company�� initial focus is on the facial aesthetics market. The Company�� product candidate, ATX-101, is a injectable drug in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted, ATX-101 has exhibited results in the reduction of submental fat. ATX-101 contains a synthetic form of sodium deoxycholate. In the United States and Canada, the Company is conducting two pivotal Phase III trials of ATX-101 for the reduction of submental fat. The Company initiated this pivotal Phase III clinical program, with planned enrollment of 1,000 patients, in March 2012.
In Europe, Bayer, its collaborator outside the United States and Canada, recently completed two pivotal Phase III trials of ATX-101 for the reduction of submental fat. In these multi-center, randomized, double-blind, placebo-controlled pivotal trials involving 723 patients, ATX-101 resulted in a reduction in submental fat, as assessed by a validated clinician scale and a patient satisfaction scale.
ATX-101 contains a synthetic form of sodium deoxycholate. ATX-101 is designed to be a locally-injected drug that causes proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue. Upon subcutaneous injection under the skin, ATX-101 disrupts cell membranes in protein-poor tissues, such as fat, while being attenuated by interactions with protein-rich tissue, such as skin, muscle and blood vessels. This attenuation by protein-rich tissue results in the preferential destruction of adipocytes by ATX-101. The destruction of adipocytes, or adipocytolysis, elicits a natural response, in which macrophages are attracted to remove cellular debris and fat particles t! hrough the lymphatic system. The macrophages also emit low levels of chemical messengers, known as cytokines, which attract fibroblasts, another cell type, to the area. Fibroblasts produce collagen, and it is believed that new collagen production, or neocollagenesis, promotes retraction of the skin in the areas of fat reduction. The fat removal process with ATX-101 is incremental with each treatment, thereby allowing for control of the aesthetic outcome.
Advisors' Opinion:- [By John Udovich]
On Tuesday, small cap biotech stock Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) surged around 25% after announcing that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints for the reduction of so-called double chins; but if investors missed out on that rally, small caps Zeltiq Aesthetics Inc (NASDAQ: ZLTQ), Solta Medical Inc (NASDAQ: SLTM) and Cynosure, Inc (NASDAQ: CYNO) each have a piece of the aesthetic market as well. In the case of Kythera Biopharmaceuticals, its ATX-101 can be injected to deal with double chins���meaning its less invasive than liposuction as the drug dissolves fat cells but leaves other tissue alone. JP Morgan has noted:
- [By Lisa Levin]
Kythera Biopharmaceuticals (NASDAQ: KYTH) shares surged 24.40% to touch a new 52-week high of $41.71 after the company reported positive ATX-101 top line phase III trial results for the reduction of submental fat.
- [By Roberto Pedone]
Kythera Biopharmaceuticals (KYTH) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. This stock closed up 12.2% to $31.99 in Monday's trading session.
Monday's Volume: 221,000
Three-Month Average Volume: 72,572
Volume % Change: 220%From a technical perspective, KYTH ripped sharply higher here right above its 50-day moving average of $26.92 with heavy upside volume. This move pushed shares of KYTH into new all-time-high territory above its previous all-time high at $31.93, which is bullish technical price action.
Traders should now look for long-biased trades in KYTH as long as it's trending above Monday's low of $28.28 and then once it sustains a move or close above its new all-time high at $32 with volume that hits near or above 72,572 shares. If we get that move soon, then KYTH will set up to enter new all-time-high territory, which is bullish price action. Some possible upside targets off that move are $35 to $37.
- [By Lisa Levin]
Kythera Biopharmaceuticals (NASDAQ: KYTH) jumped 24.43% to $41.72 after the company reported positive ATX-101 top line phase III trial results for the reduction of submental fat.
Top Tech Stocks To Buy For 2014: Navidea Biopharmaceuticals Inc (NAVB)
Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.
Lymphoseek
Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-center Phase II trial and three multi-center Phase II trials inv! olving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.
AZD4694
AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has been studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.
RadioImmunoGuided Surgery
As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.
The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.
Advisors' Opinion:- [By Erin McCarthy]
Navidea Biopharmaceuticals Inc.(NAVB) said Chief Executive Mark Pykett would leave that post around the end of this month as the company restructures its biopharmaceutical product pipeline.
- [By Sean Williams]
Another prime example here would be Navidea Biopharmaceuticals' (NYSEMKT: NAVB ) Lymphoseek which is an injectable agent used in external lymph-node imaging and intra-operative lymphatic mapping. In English this means it will dramatically improve the staging and treatment options for patients with breast cancer. Being that breast cancer was also listed as a commonly misdiagnosed cancer, this is a big step in the right direction for patient care.
- [By Lauren Pollock]
Navidea Biopharmaceuticals Inc.(NAVB) said the U.S. Food and Drug Administration has granted a priority review for an expanded use of its Lymphoseek drug for some patients with head and neck cancer. Shares dropped 5.4% to $1.97 premarket.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Tuesday’s session are Toll Brothers Inc.(TOL) and Navidea Biopharmaceuticals Inc.(NAVB)
Top Tech Stocks To Buy For 2014: Mandalay Digital Group Inc (MNDL)
Mandalay Digital Group, Inc., incorporated on September 14, 2007, through its wholly owned subsidiary, Digital Turbine, provides mobile solutions for wireless carriers globally to enable them to monetize mobile content. The Company's products include mobile application management through DT Ignite, user experience and discovery through DT IQ, application stores and content through DT Marketplace, and content management and mobile payments through DT Pay.
The Company delivers a mobile services platform that works with mobile operators and third-party publishers to provide portal management, user interface, content development and billing technology that enables the responsible distribution of mobile entertainment. Its Digital Turbine delivers end-to-end products and solutions to mobile operators, including Vodafone, Telefonica, Turkcell, Telecom Italia, SingTel, Smart, Telstra, Cricket and Singtel Optus. Its mobile services platform and billing technology enables mobile operators, original equipment manufacturers (OEMs) and third-parties to manage their content portals and storefronts.
Advisors' Opinion:- [By Monica Gerson]
Mandalay Digital Group (NASDAQ: MNDL) is projected to post a Q4 loss at $0.11 per share on revenue of $6.98 million.
Advanced Photonix (NYSE: API) is expected to post a Q4 loss at $0.01 per share on revenue of $7.04 million.
No comments:
Post a Comment